Sabinsa recently announced the introduction of a unique, new process for the manufacture of Glucosamine Sulfate. This new process incorporates the use of potassium rather than sodium as a bonding agent, creating a safer, higher quality product with increased absorption.
Demographically speaking, the most common use of Glucosamine Sulfate in conjunction with symptoms of arthritis is found among senior citizens. Consistent use of a sodium based product poses an additional risk for those already concerned about their daily intake of sodium.
Sabinsa's new patent-pending process for a potassium based product eliminates the risk of increased sodium intake and provides a high quality alternative with increased absorption characteristics.